How Vyvanse Increases Blood Pressure
Vyvanse (lisdexamfetamine) increases blood pressure through its mechanism as a CNS stimulant that inhibits the reuptake of dopamine and norepinephrine, leading to increased sympathetic nervous system activity and peripheral vasoconstriction. 1, 2
Mechanism of Action
Lisdexamfetamine, like other amphetamines, works by:
- Blocking reuptake of catecholamines: Primarily dopamine and norepinephrine at nerve terminals 1
- Promoting neurotransmitter release: Amphetamines also stimulate the release of these catecholamines from presynaptic neurons 1
- Peripheral sympathomimetic effects: The increased norepinephrine activity causes vasoconstriction of blood vessels throughout the body 3
This is not simply an "indirect" sympathomimetic effect through norepinephrine release alone. Recent evidence suggests amphetamines may also bind to trace amine-associated receptors (TAARs) in blood vessels, contributing directly to vasoconstriction independent of noradrenergic mechanisms 3.
Clinical Impact on Blood Pressure
The FDA label clearly states that CNS stimulants cause mean increases of approximately 2-4 mmHg in blood pressure and 3-6 bpm in heart rate, though some patients experience larger increases 2.
High-quality evidence confirms these effects:
- A 2025 Cochrane systematic review of 56 RCTs (10,583 participants) found amphetamines increased systolic BP by 1.93 mmHg and diastolic BP by 1.84 mmHg, with heart rate increasing by 3.71 bpm 4
- These effects persist with long-term use (≥8 weeks), indicating sustained cardiovascular stimulation rather than tolerance development 4
- In a 4-week trial of lisdexamfetamine specifically, pulse increased dose-dependently (2.8-5.2 bpm across doses), though blood pressure changes were not significantly different from placebo in that particular short-term study 5
Clinical Monitoring Requirements
All patients on Vyvanse must have blood pressure and heart rate monitored regularly because:
- 5-15% of patients experience substantially larger BP increases than the average 6
- A 2024 Swedish study found longer cumulative ADHD medication use associated with increased CVD risk, particularly hypertension (AOR 1.72-1.80 for >3 years use) 7
- Peripheral vasculopathy including Raynaud's phenomenon can occur at therapeutic doses 2
Key Clinical Pitfalls
Avoid Vyvanse in patients with:
- Known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or coronary artery disease 2
- Pre-existing hypertension (unless well-controlled and closely monitored)
Before initiating treatment:
- Obtain personal and family cardiac history, specifically asking about sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome 6
- If risk factors present, obtain ECG and consider cardiology consultation 6
During treatment:
- Monitor BP and HR at baseline and regularly throughout treatment 6, 2
- Watch for symptoms of peripheral vasculopathy (numbness, coolness, color changes in fingers/toes) 2
- Be aware that 5-15% of patients may have clinically significant BP elevations requiring intervention 6
The blood pressure increase is a direct pharmacological consequence of amphetamine's sympathomimetic properties and represents a class effect that requires ongoing clinical vigilance throughout treatment duration.